The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

In what is thought to be the first major pharma M&A deal of the year, Amgen has bought Oxford, UK-based biotech Dark Blue ...

True Blue Behavioral Health provides a comprehensive Dialectical Behavior Therapy (DBT) program. The program includes weekly individual therapy and group skills training sessions, as-needed phone ...

Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...

California healthcare innovator Amgen, which already has facilities at Cambridge Science Park, has made a new and incisive acquisition in the UK - buying Oxford University spin-out Dark Blue ...